ReviewLife (Basel, Switzerland)2025
DynamX Bioadaptor as an Emerging and Promising Innovation in Interventional Cardiology.
Review in Life (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cardiovascular Diseases: From Basic Research to Clinical Application-3rd Edition.Life (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronary artery disease (CAD) remains a major cause of mortality worldwide. Among the standard therapeutic approaches are percutaneous coronary interventions (PCI) employing stents. The main limitation of the procedure lies in the permanent stiffening of the vessel wall. The DynamX Bioadaptor, representing a new generation of vascular stents, combines the advantages of standard implants with a unique mechanism-"uncaging." Its helical structure, linked by a biodegradable material, enables the restoration of the vessel's natural functions. This breakthrough concept in interventional cardiology holds the potential to establish a new standard of care for patients suffering from CAD. In this work, we aim to synthesize the available evidence concerning the characteristics of the DynamX Bioadaptor and its impact on vascular physiology. We provide a comprehensive review and evaluation of current clinical reports on its use, analyzing the available literature in comparison with other stent technologies. Recognizing that the DynamX Bioadaptor is a relatively recent innovation, we also seek to identify existing gaps in the literature and propose future directions for research to fully assess its long-term clinical potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.